Dosing and uses of Parsabiv (etelcalcetide)
Hyperparathyroidism
Pending FDA approval for treatment of secondary hyperparathyroidism (SHPT) for patients with chronic kidney disease (CKD) on hemodialysis
Pharmacology of Parsabiv (etelcalcetide)
Mechanism of action
Calcium-sensing receptor (CaSR) agonist
